Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.

Immunic has secured $400 million in financing, setting the stage for the readout of its phase 3 multiple sclerosis (MS) data.